Home From Drew Altman

From Drew Altman

Drew Altman is president and chief executive officer of KFF, a position he has held for more than 30 years since founding the modern-day KFF organization in the 1990s. He is a leading expert on national health policy issues and an innovator in health journalism and the nonprofit field.

View full bio | Read Dr. Altman's Beyond the Data columns

Photo of Drew Altman

President’s Message

“KFF is an independent source of health policy research, polling, and journalism. We have three major program areas: KFF Policy; KFF Polling; and KFF Health News (formerly Kaiser Health News), which conducts specialized public health information campaigns. Learn more about the organization. 

What’s unique about KFF, however, can’t be found in any description of our programs because we’re more than a sum of our parts. KFF is a one-of-a-kind information organization. Not a policy research organization. Not a polling organization. And not a news organization. But rather, a unique combination of all three. That’s the vision behind KFF, and it's this combination that allows us to leverage our combined expertise and assets to play our national role on health policy.” Read more

Beyond the Data

In his “Beyond the Data” columns, Drew Altman discusses what the data, polls, and journalism produced by KFF mean for policy and for people.

Americans May Be Smarter About Vaccines Than You Think

In a new column that analyzes recent KFF polling, Founding President and CEO Dr. Drew Altman concludes that only a sliver of the public hold definitive anti-science, anti-vaccine views, and are greatly outnumbered by the people who believe established science, with even more Americans stuck in a “muddled middle.” He writes, “when you see reports of social media engagement spiking about a health myth, don’t overreact. It’s more likely than not that it’s a relatively small group of Americans who already believe it talking to themselves, and they are vastly outnumbered by those who believe the science.”

View All Beyond the Data Columns

View the Latest: From Drew Altman

Filter

List Grid

71 - 80 of 344 Results

  • The Sleeper Health Cost Policy

    From Drew Altman

    In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.

  • Why Drug Price Negotiation Has Staying Power

    From Drew Altman

    In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.

  • Persistent Vaccine Myths

    From Drew Altman

    With news that the country has now vaccinated half of its population with at least one dose, This Drew Altman Axios column highlights the persistent COVID-19 vaccine myths that are believed by a substantial portion of the unvaccinated population and discusses the options to address vaccine misinformation.

  • Corporate Leaders Are Getting Bullish On Government Action On Health Care Costs

    From Drew Altman

    In this Axios column, Drew Altman explores whether the long struggle with rising health costs has caused the tide to turn in corporate leaders’ attitudes towards government involvement in controlling health spending and whether it is part of a larger shift in comfort with government action to solve problems.

  • Where To Start To Build Vaccine Confidence

    From Drew Altman

    In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them." But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of 'wait and see' Americans.”

  • Vaccine Confidence Isn’t The Main Obstacle To Reaching Herd Immunity

    From Drew Altman

    In this Axios column, Drew Altman paints a more optimistic picture of the prospects for getting to herd immunity as vaccine confidence grows, but underscores the urgency of building vaccine confidence in Black and Latino communities where barriers to access and good information are obstacles to getting vaccinated.